STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
A deal for smart-ring maker Oura to acquire a telehealth company is raising conflict-of-interest questions for Eli Lilly
Pharmalittle brings news of Lilly's conflict questions and a DEA approval for a narcolepsy medication. The DEA has granted Orzeyful, a new treatment for narcolepsy, a Schedule IV status, indicating low potential for abuse and dependence. This approval comes after the DEA removed the final regulatory hurdle for Orzeyful's rollout in the U.S. The drug's list price in the U.S. is set at $16,500 for a 60-tablet bottle.
Around 120,000 Americans are affected by the sleep disorder. Pfizer, on the other hand, is discontinuing its hormone replacement therapy Premarin in Canada due to an internal review. Premarin, a vaginal cream and oral tablets used to manage menopause symptoms, has been in short supply in Canada since June with no additional batches planned.
Demand for hormone replacement therapy has surged, especially in the U.S., where prescriptions have climbed since the FDA removed safety warnings a year ago. Other menopause treatment products are also experiencing supply issues in Canada.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
